Drugmakers sure are eager to talk about drug prices lately

On a Thursday morning conference call about Celgene Inc.’s latest financial results, Chief Executive Mark Alles brought up drug prices right away.

It’s a subject that most drugmakers have been reluctant to speak about — until recently, that is. After price hikes made by Pfizer Inc. PFE, +0.35% sparked a Twitter standoff with President Donald Trump in mid-July, the company agreed to defer price increases until next year.

Plenty of others have followed in kind, and the trend has extended into corporate earnings this week.

But many question whether these agreements are just a savvy public relations exercise, especially as the Trump administration pushes a drug price plan that largely targets other industry players.

>>> Original Source <<<